Botulinum Toxins - Daxxify
Customize your policy alerts
Sign up for Cigna Policy IP0588 alerts
Get alerted when Policy IP0588 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and benefit coverage for Daxxify administered for cervical dystonia in adults. It establishes medical-necessity criteria, dosing limits, documentation requirements, noncovered cosmetic uses, and applicable billing code requirements.
Cervical dystonia approval criteria were revised to require that the patient be at least 18 years old, have documented cervical dystonia, have documented sustained head torsion and/or tilt with limited neck range of motion, and receive prescribing by or consultation with a specified specialist.
The maximum Daxxify dose for cervical dystonia was reduced from 300 units to 250 units, administered no more frequently than once every 3 months.
The conditions-not-covered section was updated to focus on cosmetic uses.
CPT code 64616 was removed from the coding information.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.